Antibiotics

An examination of broad-spectrum antibiotic use in this patient population is essential for developing strategies to mitigate the risk of these infections.

James S. Lewis, PharmD, FIDSA, discusses the need for the development of non-antibacterial options against infections, such as monoclonal antibodies.

Daniel Diekema, MD, explains how the microbiology lab works to provide optimal drug selection for empiric and directed therapy.

While a new FDA report shows antibiotic resistance remains low among many food-borne bacteria, some pathogens are increasingly showing multidrug resistance.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

Daniel Diekema, MD, explains why the microbiology laboratory should be a part of antimicrobial stewardship programs.

James S. Lewis, PharmD, FIDSA, explains why addressing issues surrounding antibiotic use in veterinary medicine is crucial in the fight against antibiotic resistance.

What is pharma doing about the impending antibiotic resistance “apocalypse?”

Part 3 of our series looks at

Three antimicrobial susceptibility tests have been cleared by the FDA concurrently with the launch of a new antibiotic Baxdela, to help guide its use.

At this year’s annual CHEST meeting, Theravance Biopharma investigators report positive new data pertaining to VIBATIV gleaned from the TOUR study.

Another prong in the battle against resistant Gram-negative infections is the addition of beta-lactamase inhibitors to restore or improve the activity of older carbapenems.

Alan Gross, PharmD, discusses testing options for multidrug-resistant pneumonia.

Investigators in China have found that the presence of the MCR-1 gene has increased in humans over a period of 5 years.

Antimicrobial-resistant organisms, particularly Gram-negative bacteria, present a critical threat and a substantial burden.

A proven marker of host response to bacterial infection may help providers avoid contributing to the rise of antibiotic resistance.

Alan Gross, PharmD, postulates why one in four patients experienced treatment failure for community-acquired pneumonia in a recent study.

Researchers turn to the literature to assess if the antibiotic cefepime causes neurotoxicity.

James S. Lewis, PharmD, FIDSA, shares different proposals shared in the health care community to incentivize pharmaceutical companies to develop needed drugs.

Michael N. Dudley, PharmD, explains how VABOMERE was associated with a higher overall cure rate and lower mortality compared with the best available therapy in patients with CRE infections in a recent trial.

New research supports that allergy evaluation is an inexpensive intervention and that given the downstream benefits, it may well be cost-effective.

Monica Mahoney, PharmD, BCPS-AQ ID, explains the first-line empiric therapy for candidemia.

Researchers in a pediatric hospital in Tokyo see positive results following the implementation of an antibiotic stewardship program limiting carbapenem use.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Amanda Paschke, MD, MSCE, explains the advantage of administering a beta-lactam in combination with a beta-lactamase inhibitor.

Researchers from the University of Colorado Boulder have developed nanoparticles capable of boosting the effectiveness of antibiotics against drug-resistant superbugs.

Evelyn J. Ellis-Grosse, PhD, chief scientific officer of Zavante Therapeutics, explains why Zavante Therapeutic’s fosfomycin is a unique, novel antimicrobial.

Christopher McCoy, PharmD, shares the protocol for approaching patients who may have a beta-lactam allergy.

A new study pulls back the curtain into a complex web of resistance, colonization, and the challenges of antimicrobial resistance in this setting.

The message for clinicians is to be vigilant. Look for candidemia and C. difficile infection occurring together.